Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial
Language English Country Germany Media print-electronic
Document type Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial
PubMed
29611083
DOI
10.1007/s10067-018-4074-6
PII: 10.1007/s10067-018-4074-6
Knihovny.cz E-resources
- Keywords
- Antirheumatic agents, Clinical trial, Geographic locations, Golimumab, Rheumatoid arthritis,
- MeSH
- Antirheumatic Agents therapeutic use MeSH
- Adult MeSH
- Remission Induction MeSH
- Drug Therapy, Combination MeSH
- Middle Aged MeSH
- Humans MeSH
- Methotrexate therapeutic use MeSH
- Adolescent MeSH
- Young Adult MeSH
- Antibodies, Monoclonal therapeutic use MeSH
- Prospective Studies MeSH
- Arthritis, Rheumatoid drug therapy MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Severity of Illness Index MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial, Phase III MeSH
- Multicenter Study MeSH
- Randomized Controlled Trial MeSH
- Names of Substances
- Antirheumatic Agents MeSH
- golimumab MeSH Browser
- Methotrexate MeSH
- Antibodies, Monoclonal MeSH
GO-MORE (NCT00975130) was a large open-label, multinational, multicenter, prospective phase 3 trial evaluating add-on therapy with golimumab in biologic-naïve patients with active rheumatoid arthritis (RA). The objective of this post hoc analysis was to examine regional differences in baseline disease activity and remission rates following golimumab treatment for RA. This was a planned, descriptive post hoc analysis of data from the GO-MORE trial. Baseline disease activity and remission were defined as moderate or severe based on EULAR criteria. This analysis included 3280 participants from the GO-MORE trial. All participants included in this analysis had high or moderate disease activity at baseline. At baseline, high disease activity was least common in Europe (71.0%), Canada (77.0%), and the Middle East (78.2%) and most common in Latin America (90.7%), South Africa (91.5%), and Asia (92.5%). Month 6 remission rates were highest in South Africa (29.1%), Europe (27.9%), and the Middle East (27.3%) and lowest in Canada (19.7%), Latin America (17.2%), and Asia (15.0%). Higher rates of remission in each geographical region generally corresponded with lower baseline disease activity. We suspect that access to care and implementation of the treat-to-target strategy were the most important determinants, but this apparent relationship needs to be confirmed in further studies that include a statistical analysis of prognostic indicators.
AGAR UFM 6 Avenida 7 55 zona 10 01010 Guatemala City Guatemala
Institute of Rheumatology Na Slupi 4 128 50 Praha 2 Czech Republic
MSD Clos du Lynx 5 1200 Woluwe Saint Lambert Belgium
MSD Via Vitorchiano 151 00189 Rome RM Italy
Sheba Medical Center Tel Hashomer Emek HaEla St 1 Ramat Gan Israel
See more in PubMed
Ann Rheum Dis. 2014 Aug;73(8):1477-86 PubMed
Rheumatology (Oxford). 2016 Aug;55(8):1466-76 PubMed
Reumatol Clin. 2015 May-Jun;11(3):144-50 PubMed
Rheum Dis Clin North Am. 2009 Nov;35(4):745-57, vii-viii PubMed
Arthritis Care Res (Hoboken). 2012 Aug;64(8):1135-43 PubMed
Ann Rheum Dis. 2014 Mar;73(3):492-509 PubMed
Ann Rheum Dis. 2016 Jan;75(1):3-15 PubMed
Ann Rheum Dis. 2010 Apr;69(4):631-7 PubMed
Ann Rheum Dis. 2016 Mar;75(3):540-6 PubMed
Lancet. 2009 Jul 18;374(9685):210-21 PubMed
Ann Rheum Dis. 2009 Nov;68(11):1666-72 PubMed
Ann Rheum Dis. 2013 Mar;72 (3):381-9 PubMed
Arthritis Rheum. 2011 May;63(5):1200-10 PubMed
